Overexpressed NEAT1 in K562 and KCL22 cells aggravated cell apoptosis and inhibited cell viability of CML cells, implying NEAT1 as a potential therapeutic target for CML. This evidence concerns the gene NEAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.